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Abstract
USP25m is the muscle isoform of the deubiquitinating (DUB) enzyme USP25. Similarly to most DUBs, data on USP25
regulation and substrate recognition is scarce. In silico analysis predicted three ubiquitin binding domains (UBDs) at the N-
terminus: one ubiquitin-associated domain (UBA) and two ubiquitin-interacting motifs (UIMs), whereas no clear structural
homology at the extended C-terminal region outside the catalytic domains were detected. In order to asses the contribution
of the UBDs and the C-terminus to the regulation of USP25m catalytic activity, ubiquitination state and substrate
interaction, serial and combinatorial deletions were generated. Our results showed that USP25m catalytic activity did not
strictly depend on the UBDs, but required a coiled-coil stretch between amino acids 679 to 769. USP25 oligomerized but this
interaction did not require either the UBDs or the C-terminus. Besides, USP25 was monoubiquitinated and able to
autodeubiquitinate in a possible loop of autoregulation. UBDs favored the monoubiquitination of USP25m at the
preferential site lysine 99 (K99). This residue had been previously shown to be a target for SUMO and this modification
inhibited USP25 activity. We showed that mutation of K99 clearly diminished USP25-dependent rescue of the specific
substrate MyBPC1 from proteasome degradation, thereby supporting a new mechanistic model, in which USP25m is
regulated through alternative conjugation of ubiquitin (activating) or SUMO (inhibiting) to the same lysine residue (K99),
which may promote the interaction with distinct intramolecular regulatory domains.
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Introduction
Ubiquitin (Ub) modifies protein architecture when covalently
attached to its substrates. Besides being the main tag for sending
misfolded proteins to the proteasome, Ub also plays a relevant role
in protein-protein interaction and modulation of catalytic activity
or protein fate [1–3]. The intrincate Ub-signalling networks
require a tight regulation of both conjugation and deconjugation
processes, and the final fate of the modified protein depends on
several factors, including the ubiquitin chain length and the
configuration of Ub-Ub linkages within the poly-Ub chain [4,5].
In particular, monoubiquitination is not related to proteasome
targeting but to modification of enzymatic activity and subcellular
localization [6,7]. On the other hand, ubiquitin-like molecules
(Ubls), such as SUMO, are also covalently bound to their
substrates, and thus are conjugated, deconjugated and recognized
by specific enzymes and their targets [8,9].
Although many studies have investigated the activation of Ub
and its transfer to substrates [10], the biochemical mechanisms
downstream of ubiquitination are not completely understood. It is
known that the subsequent events are mediated by ubiquitin
receptors, which interact with monoubiquitin and/or polyubiqui-
tin chains through small (20–150 amino acids) Ub-binding
domains (UBDs) [11,12]. At least fifteen classes of UBDs have
been annotated [13] and this profusion of motifs has launched the
study of Ub signalling by: i) providing clues on the roles and modes
of action of ubiquitinated substrates, and ii) showing that UBD-
containing proteins interact either with Ub or with a ubiquitinated
protein. UBD-Ub interactions are usually weak and generate a
dynamic protein network that is rapidly assembled and disassem-
bled, thus hindering their study. Moreover, UBDs can modulate
the activity of the host protein, as intramolecular interactions
between a UBD and a Ub moiety covalently attached to another
region of the same protein lead to structural changes that alter the
enzymatic activity [11,12].
UBDs are found not only in proteins that interact with
ubiquitinated substrates, but also in ubiquitinating or deubiquiti-
nating enzymes. The deubiquitinating enzymes (DUBs) hydrolyze
the Ub moieties conjugated to substrates and thus, process newly
synthesized Ub, recycle Ub, or edit polyUb chains [14,15].
Ubiquitination, like phosphorylation, is reversible [16] and,
therefore, DUBs can affect the stability and fate of Ub-conjugated
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is assumed that the presence of UBDs in DUBs favor the specific
recognition of the ubiquitin modifications, whereas the N- and C-
terminal long extensions flanking the DUB-conserved catalytic
core may be involved in substrate recognition irrespective of their
ubiquitination state.
Data on the substrate specificity and physiological function of
most DUBs, including USP25, are still scanty. USP25 encodes
three different protein isoforms produced by alternative splicing:
two of them are expressed ubiquitously, while the longest
(USP25m) is restricted to muscle tissues [17] and is upregulated
during myogenesis. Among several sarcomeric substrates,
USP25m was reported to specifically interact and rescue MyBPC1
(Myosin Binding Protein C1) from proteasome degradation,
thereby raising its cellular half-life [18].
We aimed to identify structural domains relevant for USP25m
regulation. By in silico analysis we identified three potential UBD
signatures in the N-terminal region of USP25m. Here, we
characterized USP25 by assessing the contribution of these UBDs,
as well as the long C-terminal region of USP25, to the catalytic
activity. Our results showed that USP25m was monoubiquitinated
in cultured cells, and that the UBDs modulated this modification.
The preferential site for monoubiquitination is lysine 99 (K99), a
residue that has been recently reported to be also the target of
sumoylation [19,20]. According to our results, mutation of the K99
residue diminishestherescueofthespecificsubstrateMyBPC1from
proteasome degradation. In view of these results and those of other
authors [19], we propose a novel mechanistic model for USP25m
regulation in which the same lysine residue can be either
ubiquitinated or sumoylated, and these mutually exclusive modifi-
cations have opposite effects on the enzyme activity. This regulatory
model bridges the Ub and SUMO pathways and may be
extrapolated to other ubiquitin-specific proteases.
Results
Mutation of the Cys178 catalytic residue abrogates
USP25m deubiquitinating activity
USP25m sequence (1125 aa) alignments revealed five highly
conserved distinct motifs (I to V), embedded in two domains (USP1
and USP2) characteristic of the ubiquitin-specific protease family
(UBPs, USPs in humans) [17]. The conserved catalytic triad (Cys,
Asp and His), in which Cys-178 was the presumed key residue for
DUB activity, was located in the motifs I, II and IV, respectively
(Figure 1A). Evidence of Cys-178 direct role in USP25m DUB
activity was obtained by site-directed mutagenesis to Ser (C178S
mutant). A deubiquitinating activity assay for USP25m was used to
verify this hypothesis. USP25m and Ub-b-Galactosidase co-
transformation in BL21 cells rapidly induced the proteolysis of the
fusion between Ub and b-Gal (Figure 1B). This proteolityc activity
was not observed with the C178S mutant, thus showing that Cys-
178 is essential for the deubiquitinating activity of USP25m.
The deubiquitinating activity of USP25m depends on the
presence of a long coiled-coil stretch, but does not
require the N-terminus Ubiquitin Binding Domains
In silico homology searches across several motif databases
revealed three Ubiquitin Binding Domains at the N-terminus of
Figure 1. USP25 domain dissection and their contribution to the catalytic activity. A. Sequence homologies revealed five highly conserved
USP motifs (I to V) in two domains (USP1 and USP2) that catalogue USP25m as a deubiquitinating enzyme. Cys-178 is the putative active site of the
enzyme, since it is conserved in all analyzed members of the family. B. Deubiquitinating activity assays in E.coli cells co-transformed with the
recombinant substrate Ub-bgalactosidase and either wild type (WT) USP25m or the C178S mutant confirmed that Cys 178 is the active site of
USP25m. bgal immunodetectection shows a lower band using WT USP25m, indicating hydrolysis of Ub from bgal, while the mutated form is
catalytically inactive and displays the band of the uncleaved fusion Ub-bgal. Note that the endogenous b-galactosidase is of lower molecular weight.
doi:10.1371/journal.pone.0005571.g001
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domains are known to interact with ubiquitinated proteins,
although they seem not to be required for catalytic activity.
To assess whether the UBA and UIM domains contribute to
USP25m deubiquitinating activity, we co-expressed GST epitope-
tagged deletion mutants of USP25m, which lacked one or several
Figure 2. Localization of the USP25m UBDs and analysis of their contribution to the deubiquitinating activity. A. USP25m contains one
UBA and two UIM (USP25_1, USP25_2) domains, as shown by alignments with other UBAs or UIMs. B. Schematic representation of the USP25m C-
terminal and UBD deletion mutants: DUBA (D19-58 aa, inclusive), DUIM1 (D96-115 aa, inclusive), DUIM2 (D121-141 aa, inclusive), DUBA-UIM1 (D19-
115 aa, inclusive), DUBA-UIM1-UIM2 (D19-141 aa, inclusive), DUIM1-UIM2 (D96-141 aa, inclusive). The constructs bearing serial deletions of USP25m at
the C-terminus are also shown (E679X, E769X, Q863X, E1020X). C. Deubiquitinating activity assays indicated that UBDs were not required to cleave off
ubiquitin (left upper panel). The mutant USP25mE679X was unable to hydrolyze Ub from the Ub-bgal substrate, indicating that the region between
the amino acids 679 and 769 was required for enzymatic activity (right upper panel). The empty GST vector and the full length USP25m were
respectively used as negative and positive controls. The expression level of each USP25m mutant was comparable (lower panels).
doi:10.1371/journal.pone.0005571.g002
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Gal in E. coli. Under these conditions, the deubiquitinating
activity-assay clearly showed that deletion of UIM1, UIM2 and
UBA domains, alone or in combination, did not abolish neither
diminish the USP25m DUB-activity compared to the wild type
enzyme (Figure 2C, left panel).
USP enzymes are usually proteins of high molecular weight,
which stretch at the N- and/or the C-terminus of the USP
catalytic domains. These extensions have been proposed to be
involved in substrate recognition, regulation of the catalytic
activity or subcellular localization. USP25 stretches more than
450 amino acids at the C-terminus, including the muscle-specific
peptide (introduced by alternative spliced exons 19a and 19b, see
Figure S1). We had previously shown that this tissue-specific
peptide (70 amino acids) was required for recognition and rescue
from proteasome degradation of sarcomeric substrates [18], but
except for this experimental evidence, the function of this long C-
terminus remained unassigned. We decided to perform serial
deletions by introducing STOP codons by site-directed mutagen-
esis at positions E679X, E769X, Q863X and E1020X. As in silico
searches did not find any functional motif or obvious homology in
this region, the positions for the STOP codons were chosen by
avoiding to impair secondary structures such as alpha helices or
coiled-coils (Figure 2B).
In contrast with the results obtained with the UBD mutants, the
analysis of the serial truncated proteins at the C-terminus of the
USP25m protein clearly showed that mutant E679X was
incapable of cleaving off the ubiquitin moiety of the Ub-b-gal
protein, whereas mutants E769X, Q863X and E1020X still
retained the enzymatic activity (Fig. 2C right panel). Thus, even
though the catalytic USP domains relevant for DUBs were present
in E679X (Figure S1), the deletion of 90 amino acids between
E679 and E769 completely abrogated the deubiquitinating activity
of USP25. It is worth noting that in silico predictions showed a long
coiled-coil domain in this region.
As UBDs have also been involved in shifts in subcellular
localization, we asssessed whether the wild-type USP25m and
UBD-deleted constructs, either in their catalytically active or
inactive forms, showed different localizations. No change in the
distribution pattern was observed in any condition, indicating that
the UBA and UIM domains were not required for targeting
USP25 to its localization (Figure S2). We also monitored Ub
distribution on the same cells and ruled out a possible effect on the
accumulation of ubiquitinated proteins (Figure S2), as described
for other USPs [21]. Nor did the USP25 C-terminal truncated
mutants show any shift in their subcellular localization, as they all
remained cytosolic in transient transfections on cultured cells (data
not shown).
USP25m forms complexes by dimerization/
oligomerization
The dynamic nature of the Ub-pathway requires the formation
of complexes in which enzymes and cofactors are transiently
recruited, not only E2 and E3 ligases but also DUBs [22–24]. We
explored whether USP25m was able to dimerize/oligomerize. To
this end, we used two tags, c-Myc and GFP, fused to the wild-type
USP25m protein and each of the deletion USP25m mutants,
respectively. Co-immunoprecipitation assays showed the interac-
tion between the cMyc- and GFP-tagged USP25 proteins,
indicating that USP25 formed homodimeric or oligomeric
complexes in vivo (Figure 3A). The catalytically inactive enzyme,
as well as all the UBD deletion mutants, also dimerized (or
oligomerized) (Figure 3A and 3B). Similar results were obtained
when assaying the C-terminal mutants (Figure 3C). A double
mutant USP25mD153-E679X (in which the first 153 amino acids
have been deleted, and the protein is truncated at amino acid 679)
could also oligomerize (Figure 3C). Therefore, neither the UBDs
nor the C-terminus of USP25m were required for this interaction.
Taken together, these results suggested that the region between
amino acids 153 to 679, which contained the USP domains and
was not deleted in any construct, was relevant for dimerization/
oligomerization.
Native gel electrophoresis followed by western blot immunode-
tection confirmed that USP25 was included in high molecular
weight complexes (.250 kDa, data not shown). As non-denatur-
ing conditions were used to detect protein complexes, the
dimerization (oligomerization) of USP25 could either be direct
or require some other substrate/partners.
USP25m was ubiquitinated and autodeubiquitinated,
and the target residue for ubiquitination in vivo is K99
Many E3 ligases and some DUBs undergo post-translational
modifications, such as ubiquitination or sumoylation, which
modulate the recognition of their substrates [25]. Of particular
interest was to determine whether USP25m was modified by
ubiquitin, given the deubiquitinating activity of the enzyme and
the fact that both, mono- and poly-ubiquitination have been
widely reported to regulate enzyme function. We investigated the
USP25m ubiquitination status in HEK293T cells transiently co-
transfected with His(6x)-Ubiquitin and Myc-tagged USP25m
constructs. Immunodetection of USP25m showed an additional
higher molecular weight-band (Figure 4A), around 25% of the
total USP25m. This band was much weaker in lysates of cells that
did not over-express the Ub construct, indicating that only a
fraction of USP25m was ubiquitinated in vivo under our
experimental conditions. Unexpectedly, the expression of the
USP25m catalytically inactive form produced a much stronger
high molecular-weight band (Figure 4A, lanes 3–4), which
amounted to 60% of total USP25m when co-transfected with
the Ub construct (Figure 4A, histogram). The fact that the
proportion of modified enzyme was increased in the catalytically
inactive C178S mutant, strongly indicated that the wild-type
enzyme is able to autodeubiquitinate. Taken together, these results
indicate that USP25m is mono-ubiquitinated in vivo, and that the
enzyme may revert this modification by autodeubiquitination.
To examine the possible involvement of UIMs in USP25m
ubiquitination [26,27], we assayed the ubiquination state of the
UBD deletion constructs. The deletion of any UIM and UBA
domains, or their combination, prevented, at least partially,
USP25m mono-ubiquitination (Figure 4B, upper panel). The
mono-ubiquitinated bands were more apparent if the catalytically
inactive forms of the deletion constructs were used (Figure 4B,
lower panel). In all deletions and constructs the proportion of
modified protein was clearly lower than that of the full-length
USP25m.
To further study USP25m ubiquitination, we performed a Ni
2+
pull-down assay in cells co-expressing the different USP25 mutants
together with His-tagged Ubiquitin. We recovered ubiquitinated
USP25m proteins in all UBD deletion mutants (Figure 4C). We
also tested the C-terminus deleted USP25m forms; all of them
showed intense high molecular-weight bands indicative of mono-
and possible multi- or poly-ubiquitination. Noticeably, when
testing the mutant that lacked the coiled coil region (E679X), most
of the protein was Ub-modified. This result supported the
proposed autodeubiquitination activity, as this mutant was
catalytically inactive. To discern whether this multiple band
pattern was caused by poly-ubiquitination to tag the deleted
USP25m proteins to proteasome degradation, we performed an
Ubiquitination Regulates USP25
PLoS ONE | www.plosone.org 4 May 2009 | Volume 4 | Issue 5 | e5571Figure 3. Dimerization/oligomerization of USP25m. A. Coimmunoprecipitation assays after co-expressing two differently tagged forms (cMyc-
or GFP-) of either the wild-type USP25m or the C178S mutant, showed that USP25 dimerized in vivo (upper panel). The catalytic Cys was not required
for interaction. The empty GFP vector was used as a negative control. B. The same co-immunoprecipitation experiment co-expressing the cMyc-
USP25m with each of the UBD deletion mutants fused to GFP showed that none of the UBDs was critical for dimerization or formation of the
complex. Last lanes of the panels correspond to the co-immunoprecitation of the two mutants bearing the deletion of the 3 UBD domains (D19-141,
inclusive). Single transfection with the GFP-USP25m construct was used as a negative control. C. The same assays using the constructs with serial
deletions of the C-terminal region of the enzyme showed that the C-terminus was not required for dimerization of USP25m. The last lane of the
panels at the left corresponds to the cotransfection with two differently tagged E679X mutants. Single transfection with the GFP-USP25m construct
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(Figure 4D). USP25m full-length as well as the UBD deletion
mutants were stable at 16 hours treatment, supporting mono- and
multi-Ub modification. In contrast, the protein levels of the C-
terminal deletion mutants were clearly increased when the
proteasome was inhibited, indicating poly-ubiquitination
(Figure 4D), therefore the most C-terminal region is required for
USP25 estabilization.
To identify the lysine residue involved in the mono-ubiquitina-
tion, we co-transfected cells with the mutant USP25mC178S with
His(6x)Ub, enriched the lysate in USP25m forms by immunopre-
cipitation with an anti-cMyc antibody, and analysed the obtained
bands by LC-ESI-QTOF mass spectrometry. One Ub-modified
peptide appeared consistently, indicating that K99 was the most
likely acceptor site (Table 1). This lysine is located at the beginning
of UIM1 and most interestingly, had been previously reported to
be the main acceptor for USP25 sumoylation, suggesting a dual
regulatory role for this residue. Given that deletion of UIMs,
although clearly diminishing USP25 ubiquitination, did not
completely preclude it, other less preferential sites might become
alternative acceptor sites for ubiquitination.
Taken together, our results strongly suggest that: i) USP25m
was ubiquitinated and underwent autodeubiquitination, ii) UIM1,
UIM2 and UBA domains promoted, but were not strictly required
for monoubiquitination, iii) the C-terminal region is relevant for
the protein stability and, when deleted, USP25m is polyubiqui-
tinated and targeted for proteasome degradation, and iv) the
preferential target lysine for ubiquitination is K99.
Given that USP25 was also reported to be a target for SUMO
[19], we assayed other potential USP25 post-translational
modifications. The in vitro assay showed that indeed SUMO-1
and SUMO-2 were conjugated to USP25m. In addition, our
results in cultured cells revealed that USP25m was phosphorylated
(in Tyr and Ser/Thr residues) and acetylated, and that these
modifications were independent of USP25m catalytic activity, as
the wild-type protein and the inactive mutant were similarly
modified (Figure S3). Further work is needed to assess whether
these modifications modify the catalytic activity of USP25.
UBDs modulate USP25m substrate recognition
AlthoughthetargetsofmostDUBs areunkown,USP25isaDUB
that specifically recognizes and binds its substrates in physiological
conditions. We previously reported that the muscle-specific isoform
USP25 interacted with MyBPC1, and that the DUB activity of
USP25m rescued this substrate from proteasome degradation. This
recognition was highly specific and depended on the peptide
encodedbythemuscle-specificexons19a and 19b,astheubiquitous
USP25 isoform was unable to rescue this substrate [18].
Given the reported relevance of UBDs in the regulation of
protein folding and modular domain interactions, we were
prompted to test the effect of the absence of UBA and/or UIM
domains of USP25m in the rescue of MyBPC1 from proteasome
degradation. As a positive control, the expression of the wild-type
USP25m rescued MyBPC1 to the levels attained with the MG132
proteasome inhibitor (Figure 5A). Interestingly, all the UBD
mutants recognized and rescued MyBPC1 from proteasome
degradation, although with varying efficiency (compare lane 1
with lanes 5 to 10 in Figure 5A). The activity of the mutants in
rescuing MyBPC1 was compared, considering the rescue by the
wild-type USP25m as the reference (Figure 5B). Single deletion of
the UIM2 did not significantly affect the recognition and rescue of
MyBPC1, whereas the deletion of UIM1 (2-fold) or the UBA
domains (3-fold) considerably increased the levels of MyBPC1.
The double deletion of the UIM1UIM2 decreased the rescue of
the substrate. Interestingly, the deletion of the three UBD
domains, increased the rescue of MyBPC1 up to 8-fold, indicating
that UBDs are not strictly required for MyBPC1 recognition and
rescue, but rather they are involved in the enzyme catalytic
regulation and/or access to the substrate, probably as a response
to cellular requirements. Of note, this deletion not only included
the UBDs, but also the SIM domain (SUMO-interacting motif)
and the preferential ubiquitin/SUMO target, the residue K99.
Mutation of K99 inhibits USP25m activity
As aforementioned, previous reports showed that sumoylation
of USP25 occurred at K99, and this modification inhibited
USP25m deubiquitinating activity on tetraubiquitin chains [19].
We have also showed in this work that this residue was also the
preferential target for ubiquitination. Given that the two
modifications are mutually exclusive, we hypothesized that
ubiquitination in K99 would cause the opposite effect, activating
USP25. Mutation of K99 to arginine would eliminate the
preferential sites for both, sumoylation and ubiquitination, and
we could then explore the effect of this mutation in USP25m
activity directly on MyBPC1, a physiological substrate. As
controls, we used both the wild-type enzyme and the catalytically
inactive mutant C178S.
As expected, the USP25mC178S was not able to rescue
MyBPC1 in a time-course experiment, whereas the expression of
the wild-type USP25m raised the half-life of MyBPC1, as its levels
were steadily maintained through time when protein synthesis was
inhibited (Figure 5C and [18]). Remarkably, USP25mK99R was
not able to rescue MyBCP1 from proteasome degradation, as the
MyBPC1 levels steadily declined. After 16 h treatment with
cicloheximide, the MyBPC1 levels were already decreased to 50%,
and after 24 h, the levels of MyBPC1 were much lower than those
obtained by the wild-type enzyme, although higher than those
obtained by the catalytically inactive mutant (statistical signifi-
cance p,0.05, Mann-Whitney test) (Figure 5D). If the K99
mutation merely prevented sumoylation, and sumoylation inhib-
ited USP25, then we should have expected an increase of DUB
activity for the USP25mK99R mutant. However, the fact that the
K99R mutant was less effective in rescuing its substrate indicated
that the alternative modification of this lysine, namely ubiquitina-
tion, resulted in USP25m activation.
Discussion
As DUBs are the least known members of the UPS, we studied
the physiological function of USP25 by domain dissection. We
particularly focussed in the three predicted UBDs, as these motifs
are usually clustered in the same protein and confer subtle
differences in the interaction with ubiquitinated substrates. By
generating serial and combinatorial deletions, we assessed USP25
protease activity on a recombinant substrate, and showed that all
UBD deletion mutants were catalytically active. We concluded
that these domains were not strictly required for ubiquitin
recognition or the deubiquitinating activity.
was used as a negative control (first lane). The separated panels at the right correspond to the co-immunoprecipitation of the double mutant
USP25m bearing the deletion of the first 153 amino acids and truncated at residue 679 (USP25mD153-E679X) with the wild-type USP25m, and their
positive control.
doi:10.1371/journal.pone.0005571.g003
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PLoS ONE | www.plosone.org 6 May 2009 | Volume 4 | Issue 5 | e5571Figure 4. USP25m is ubiquitinated and autodeubiquitinated. A. Immunodetection of cell lysates expressing Myc-tagged USP25m showed
one additional high molecular-weight band. This band was stronger when co-expressing His(6x)-Ub, suggesting that it corresponded to mono-
ubiquitinated USP25m. The high molecular weight bands were stronger when co-expressing His(6x)-Ub and the catalytically inactive mutant
USP25mC178S. The lower histogram shows the percentage of non-modified versus mono-Ub-conjugated USP25m. B. The same experiment was
performed co-expressing His(6x)-Ub with all the UBD USP25m deletion mutants, in combination or not with the C178S mutation. Again, the
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PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5571Figure 5. UBDs modulate substrate recognition by USP25m and K99 is the key regulatory residue. A. MyBPC1 is differentially rescued
from proteasome degradation depending on the presence of the distinct UBDs. Transfection of MyBPC1 with the empty GFP vector was used as the
negative control, and addition of MG132 was used as a positive control. B. Relative quantification of the MyBPC1 rescue by different USP25m
mutants. a-tubulin was used for normalization of protein concentration (data not shown) and USP25m expression levels were used to normalize for
transfection efficiency. The rescue achieved by the wild-type USP25m was considered as the reference (value of one). At least three different
replicates were used for quantification. Asterisks indicate statistical significance (p,0.05, Mann-Whitney test). C. The catalytically inactive C178S and
the K99R mutants behaved similarly and are unable to rescue MyBPC1 from proteasome degradation in a time-course experiment when new protein
synthesis is inhibited. The rescue achieved by expression of the wild-type USP25m was used as a control. D. The MyBPC1 levels (normalized by a-
tubulin expression) were quantified and expressed relatively to those observed at time 0 h (30 h post-transfection, before cycloheximide treatment),
which were considered 100%. The values corresponded to a minimum of three different replicates in several independent experiments. Asterisks
indicate statistical significance (p,0.05, Mann-Whitney test). CHX- cicloheximide.
doi:10.1371/journal.pone.0005571.g005
ubiquitinated band was much visible in the C178S version of the mutants. C. Ni
2+ pull-down assays to purify His(6x)Ub-conjugated proteins
confirmed that USP25m was ubiquitinated. All the mutant constructs were tested, confirming that monoubiquitination (and multi- or poly-
ubiquitination) did not depend on UBDs, neither on the presence of the C-terminus. The ratio output/input is 4. (Output samples were eluted at
pH 4.5, which could account for the slight variation in the apparent protein molecular weight compared to inputs). D. Protein stability of the USP25m
full-length and mutant constructs. Cells were grown in standard conditions (2), or treated with MG132 (+). Immunodetection of a-tubulin was used
as a loading control.
doi:10.1371/journal.pone.0005571.g004
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(E2–E3 ligases, and more recently, DUBs) form cooperative
complexes [22–24]. Our results indicate that USP25 was able to
dimerize/oligomerize. Although most cysteine proteases have not
been reported to require oligomerization for catalysis, crystallo-
graphic data showed homodimerization for another USP, USP8
[28], providing further grounds for USP25 dimerization. This
interaction could occur before or upon substrate binding, and thus
provide a means of regulation. In this context, a plausible
explanation for the formation of dimers would be USP25
intermolecular autodeubiquitination (see the model below). In
addition, dimers/oligomers could facilitate the progressive deubi-
quitination of a multi- or poly-ubiquitinated substrate, or alterna-
tively, alter the interfaces displayed for substrate recognition.
One of the reported functions of UBA and UIM sequences is
the promotion of ubiquitination of the protein in which they are
embedded, thus facilitating autoregulation [29]. In the ubiquitin
pathway enzymes, feedback self-regulation loops become more
complex, as E3 ligases promote their autoubiquitination and
DUBs, their autodeubiquination, under certain physiological
stimuli [30,31]. Evidence for mono- or multi- ubiquitination of
USP25m was gathered as a faint high molecular weight band
(around 8 kDa larger than that of USP25m) after co-expression of
USP25m and ubiquitin. Notably, this band was significantly
enriched in lysates of the catalytically inactive USP25mC178S,
further suggesting both, that it corresponded to monoubiquiti-
nated forms, and that USP25 catalyzed its own deubiquitination.
Mass spectrometry of enriched USP25mC178S samples indicated
that USP25 was conjugated to ubiquitin, and that K99 (located in
UIM1) was the main target residue. Deletion of the UBDs reduced
considerably, but did not abrogate ubiquitination of USP25m, as
in all cases ubiquitinated forms were recovered. Thus, the USP25
UBDs, in particular UIM1, enhanced the ubiquitination state of
the protein by either providing the preferred lysine residue,
directly recruiting E2 or E3 ligases, or both. In the deletion
mutants, ubiquitination might take place in alternative lysines with
less efficiency. In fact, the use of preferential and alternative lysine
residues for mono-ubiquitin conjugation had been previously
reported [32].
Concerning the ubiquitination state and fate of the wild-type
protein and the UBD mutants, we surmised that it corresponded
mainly to mono- and multi- ubiquitinated forms, not related to
protein degradation, as they were stable through time under our
conditions. In contrast, the modification of the C-terminus
mutants was compatible with polyubiquitination, as their protein
levels were increased when the proteasome was inhibited, pointing
to the relevance of the last 106 amino acids in USP25m stability.
Polyubiquitination did not appear to be related to the catalytic
activity of USP25m as: i) truncated mutants E1020X, Q863X and
E769X were enzymatically active but degraded by the protea-
some, and ii) of the two catalytically inactive E679X and C178S,
the former was polyubiquitinated and degraded, whereas the latter
was monoubiquitinated and this modification was not related to
degradation. Therefore, autodeubiquitination does not seem to be
required for USP25m stability.
Finally, we assessed the contribution of the UBD deletion
mutants to the recognition of the USP25m specific substrate
MyBPC1, considering that the requirements for the interaction
with a specific physiological substrate might be different from
those of a synthetic polyubiquitin substrate. None of the UBDs was
critical for enzyme-substrate interaction, as all the mutants rescued
the substrate from proteasome degradation. However, the effects
were distinct depending on the domains deleted or preserved. The
analysis of the contribution of the single and combined domains
suggest that the UBA domain negatively modulated the USP25
function mainly by interaction with the UIM1 domain. The effect
of the two UIM domains on the substrate rescue appeared to fit an
additive/synergical mode of action. Deletion of the three UBDs
would effectively remove all these regulatory domains, including
those involved in SUMO modification and the target K99. Given
that the overexpression of this UBD-deleted USP25 construct
caused increased rescue of MyBPC1, we interpreted that the lack
of these regulatory domains allowed USP25m free (non-regulated)
access to its substrate. UBDs then would mostly contribute to the
enzyme regulation in response to cellular requirements rather than
to strict substrate recognition.
Model for USP25m regulation: the dual role of K99
Ubiquitin and SUMO pathways may engage in cross-talk,
determining opposite fates or functions of a particular substrate,
and even compete for the same residues [33]. This seems to be the
case for USP25 regulation. Our results together with those of other
authors [19] support a combined model for the regulation of
Table 1. Peptide sequences obtained by mass-spectrometry
of enriched ubiquitinated USP25mC178S showed that Lys99 is
the preferential site for monoubiquitination.
Peptide (+Ubiquitin modification) Protein identified
KYVDPSR USP25
TPTEVWR USP25
YNDIAVTK USP25
AIKLEYAR USP25
YLSYGSGPK USP25
TEIENDTR USP25
DSRNPYDR USP25
FLAVGVLEGK USP25
VLEASAIAENK USP25
TLLEQFGDR USP25
YLFALLVGTSK USP25
AVEILKDAFK USP25
HQQTFLNQLR USP25
AEEETDEEKPK USP25
AQFLIQEEFNK USP25
LEFPQVLYLDR USP25
FEFNQALGRPEK USP25
ETGITDEEQAISR USP25
LAQEDTPPETDYR USP25
DSNGNLELAVAFLTAK USP25
LNEQAAELFESGEDR USP25
ETGPQLVGIETLPPDLR USP25
IHNKLEFPQVLYLDR USP25
SGQEHWFTELPPVLTFELSR USP25
LRESETSVTTAQAAGDPEYLEQPSR USP25
YISVGSQADTNVIDLTGDDKDDLQRA (+GlyGly) USP25 (Ubiquitinated)
EGIPPDQQR Ubiquitin
ESTIHLVLR Ubiquitin
IQDKEGIPPDQQR Ubiquitin
TITLEVEPSDTIENVK Ubiquitin
doi:10.1371/journal.pone.0005571.t001
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dual role of K99 as a target for both SUMO and ubiquitin. In
response to cellular requirements, USP25 would undergo several
modifications, in particular, monoubiquitination at K99 or
sumoylation at the same residue (Figure 6A). SUMO conjugation
at K99 (and also at the secondary site K141) depends on the
interaction with the proximal SIM domain, and results in
inhibition of the USP25 protease activity on polyubiquitinated
chains in vitro [19,20]. Therefore, in physiological conditions
sumoylation would impair the rescue of substrates from protea-
some degradation by USP25. On the contrary, ubiquitination of
K99 would result in enzyme activation by either preventing
sumoylation or by allowing new interactions. The modulation of
the active enzyme would depend then on the interplay between
the UBA and the ubiquitinated K99 in UIM1, either intra-o or
inter-molecularly (Figure 6B, for the sake of simplicity the model
only shows intramolecular recognition).
Further regulation of the enzyme activity would rely on
autodeubiquitination (either intra- or inter- molecularly in a
dimer/complex), which would make this lysine residue available
for alternative modifications, thus allowing the shift between the
enzymatic activity states (Figure 6C).
According to this model, regulation and integration of cell
signals would be exerted through the N-terminus of USP25, where
the SIM, UBDs and the preferential sites for SUMO and ubiquitin
conjugation are clustered. In this context, the deletion of the three
UBDs would remove all the regulating domains of the enzyme and
permit free access to the substrate, which would explain the higher
rescue obtained for this mutant. Indeed, we have previously
showed that the recognition of the specific substrate MyBPC1, was
dependent not on UBDs but on the peptide encoded by exons
19a19b [18].
Deubiquitinating enzymes have to integrate cellular signals and
promote dynamic interactions with their substrates, similarly to
what occurs with E2–E3 ligases. Modification of a single target
residue in USP25 by SUMO (inhibiting) or ubiquitin (activating),
combined with the cluster of SIM and UBDs domains in the same
molecule, provides new insights and open new avenues for the
study of DUB regulation concerning substrate recognition and
catalytic activity. To illustrate this statement, the USP25 closest
homolog (sharing 52% of amino acid identities) is USP28 [34], a
DUB involved in MYC stability as response to DNA damage [35].
USP28 displays UBA and UIM1 domains in the same location as
USP25, including a conserved lysine 96 that may play a similar
role in the USP28 regulation as K99 in USP25. Further work will
show whether this enzyme similarity extends from structural
domains to regulatory mechanisms.
Materials and Methods
In silico identification of USP25 structural domains
The USP25m protein sequence was analyzed using the InterPro
(http://www.ebi.ac.uk/InterProScan/) and Pfam (http://www.
sanger.ac.uk/ Software/Pfam/search.shtml) databases to search
Figure 6. Model of the USP25m activity regulation upon specific substrates. A. Post-translational modifications of USP25m concerning
monoubiquitination in Lys99 (K99) and sumoylation in K99 and K141. U: Ubiquitin; S: SUMO; UBA: Ubiquitin associated domain; SIM: SUMO
interacting motif; UIM: Ubiquitin interacting motif; USP: Ubiquitin specific protease catalytic domains; CC: coiled coil domain; 19a19b: peptide
encoded by the muscle-specific exons. B. Model on the regulation of USP25m activity through alternative and mutually exclusive conjugation of
SUMO (inhibiting) and ubiquitin (activating) on the same lysine residue (K99) (see discussion). C. The dimerization of USP25m might be relevant to the
regulation of the enzymatic activity as autodeubiquitination could occur either intra- or inter-molecular in the dimer.
doi:10.1371/journal.pone.0005571.g006
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two UIM domains at the N-terminus of USP25m.
Constructs for expression of serial and combinatorial
deletions as well as generation of USP25m point mutants
Mutants USP25mC178S and USP25mK99R were generated
by site directed mutagenesis to serine using the QuickChange Site-
Directed Mutagenesis Kit (Stratagene). Expression constructs with
the full-length USP25m cloned in pGEX-4-T1 (GE Healthcare),
pcDNA3 (Invitrogen) and pEGFP-C2 (Clontech), were used to
generate by PCR the UBD deletion mutants of USP25m (DUBA,
DUIM1, DUIM2, DUBAUIM1, DUBAUIM1UIM2 and DUI-
M1UIM2). The Accuprime TaqDNA Polymerase High Fidelity
(Invitrogen) was used to avoid possible mutations. Serial deletions
of the C-terminal USP25 region were generated by introducing a
STOP codon by site-directed mutagenesis in positions E679X,
E769X, Q863X and E1020X, and cloned into pGEX-4-T1 (GE
Healthcare), pcDNA3 (Invitrogen) and pEGFP-C2 (Clontech).
Integrity of the clones was verified by sequencing.
Ubiquitin-specific protease activity assay
The ubiquitin-specific protease activity of USP25m and of all
the mutant constructs was analyzed as described elsewhere [17].
Briefly, the corresponding cDNAs cloned in-frame in pGEX-4-T1
Amp
R downstream the glutathione-S-transferase (GST) gene, and
the plasmid pACY184 Cm
r expressing Ub-Met-b-gal (a kind gift
from Dr. M. Hoschtrasser) were co-transformed in E. coli
XL1blue. Clones resistant to both Amp and Cm were grown
and induced for 3 hours with isopropyl-b-thiogalactopyranoside
(final concentration 1 mM). Total protein extracts were analyzed
by western blot using anti-b-galactosidase mouse monoclonal
antibody (dilution 1:1000, Sigma-Aldrich) and anti-GST mono-
clonal (dilution 1:1000, Santa Cruz Biotechnology).
Co-immunoprecipitation assays
HEK293T cells were seeded on 100 mm tissue culture dishes
(2610
5 cells/dish). After 16 h, cells were transiently co-transfected
with cMyc-USP25m and GFP-USP25m, either full-length or the
deletion mutants at the N- and C- terminus, using Lipofectamine
2000 (Invitrogen). Cells were collected 42 h postransfection,
resuspended in lysis buffer (0.5% Nonidet P-40, 50 mM TrisHCl
pH 7.5, 1 mM EDTA, 150 mM NaCl and protease inhibitor
cocktail (Roche) and lysed by sonication. Protein extracts were
recovered after removal of cellular debris by centrifugation,
incubated at 4uC with 2 mg of anti-cMyc mAb (Santa Cruz
Biotechnology) during 4 hours with end-over-end mixing. The
protein-antibody complexes were removed with 1 hour incubation
at 4uC with protein G-Sepharose beads (Amersham GE-
Healthcare). After washing, bound proteins were eluted from the
beads by boiling 5 min with protein loading buffer, loaded onto
8% SDS-PAGE gels and analysed by Western Bloting using anti-
GFP pAb (1:1000, Santa Cruz Biotechnology), anti-cMyc mAb
(1:1000, Santa Cruz Biotechnology).
In vivo assessment of ubiquitin conjugation
Human embryonic kidney (HEK)293T cells were plated
(2610
6) in 10 cm Petri dishes. After 12 hours, they were co-
transfected with 6 mg of a construct expressing His(6x)-Ub (kindly
provided by Dr. M. Rodriguez) and 6 mg of pcDNA-Myc-
USP25m, or pcDNA-Myc-USP25mC178S, either in their full
length version or with the UBD-deletion mutants (DUBA,
DUIM1, DUIM2, DUBAUIM1, DUBAUIM1UIM2 and DUI-
M1UIM2), or the C- terminal (679X, 769X and 1020X) deletion
mutants, using Lipofectamine 2000 (Invitrogen). Forty-eight hours
post-transfection, cells were washed with PBS and resuspended in
1.4 ml of denaturing lysis buffer pH 8.0 (50 mM sodium-
phosphate buffer pH 8.0, 8 M urea, 300 mM NaCl, 0.5% Triton
X-100, with 10 mM iodoacetamide and 10 mM NEM, freshly
added) and stored at 280uC. Cleared cell lysates were loaded onto
8% SDS-PAGE gels and analyzed by Western blotting with anti-
cMyc monoclonal antibody (1:1000, Santa Cruz Biotechnology).
For the Ni
2+ pull-down assay, cell lysates obtained as described
above, were incubated with 80 ml of His-Select Nickel Affinity Gel
(Sigma-Aldrich) during 3 h at room temperature. After 3 washes
with the following buffer at pH 6.3 (50 mM sodium-phosphate
buffer pH 6.0, 8 M urea, 300 mM NaCl), samples were eluted by
boiling 5 minutes in 100 ml of protein-loading buffer (60 mM
TrisHCl pH 6.8, 10% glycerol, 2% SDS, 0.1% bromophenol blue
and 10% b-mercaptoethanol) and loaded onto 8% SDS-PAGE
gels. After blotting, the proteins were detected by Western as
stated above.
For further assessment of ubiquitination, cell lysates were
incubated at 4uC with 2 mg of anti-cMyc mAb (Santa Cruz
Biotechnology) during 4 hours with end-over-end mixing. The
protein-antibody complexes were removed by one hour incubation
at 4uC with protein G-Sepharose beads (Amersham GE-
Healthcare). After thorough washing, bound proteins were eluted
from the beads by boiling 5 min with protein loading buffer and
loaded onto 8% SDS-PAGE gels. Bands were excised after
Coomassie-Blue R250 staining and trypsinized. Tryptic peptides
were analyzed in MALDI-TOF/TOF (4700 Proteomics Analyzer,
Applied Biosystems) and/or in LC-ESI-QTOF (Q-TOF Global,
Micromass-Waters) mass spectrometers and submitted using a
MASCOT database search engine against non-redundant NCBi
or SwissProt databases.
MyBPC1 rescue assays and protein stability of USP25m
constructs
HEK293T cells were seeded on 24-well plates (2610
5 cells/
well). After 12 hours, cells were transiently co-transfected with
constructs expressing HA-MyBPC1 and GFP-USP25m (full-
length, or the corresponding deletion mutants), using Lipofecta-
mine 2000 (Invitrogen). When stated, the proteasome inhibitor
MG132 (10 mM, Sigma) was added to the medium during the last
16 hours of culture and collected 48 hours postransfection.
Inhibition of new protein synthesis was achieved by adding
cycloheximide (CHX, 150 mmol/ml, Sigma) to the medium 30 h
postransfection and cells were collected immediately or after 4, 16
or 24 hour treatment. Cells were washed with PBS and recovered
with 250 ml of protein loading buffer. Samples were loaded onto
8% SDS-PAGE gels and analyzed by western blotting using anti-
HA monoclonal antibody (1:1000, Santa Cruz Biotechnology) and
anti-GFP polyclonal antibody (1:1000, Santa Cruz Biotechnology)
to assess the expression levels of MyBPC1 and USP25m,
respectively. Films were scanned and quantified using Quanti-
tyOne software (Bio-Rad).
Supporting Information
Figure S1 In silico predictions of functional domains and
secondary structure of USP25m. Localization of the predicted
Ubiquitin Binding Domains (one UBA and two UIMs), the
catalytic deubiquitinating domains (USP), the peptides encoded by
the muscle-specific alternatively spliced exons (19
a and 19b), and
several potential sumoylation sites and phosphorylation sites. In
silico searches used the InterPro (http://www.ebi.ac.uk/Inter-
ProScan) and Pfam (http://www.sanger.ac.uk/Software/Pfam/
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PLoS ONE | www.plosone.org 11 May 2009 | Volume 4 | Issue 5 | e5571search.shtml) databases. The red star indicates the position of the
catalytic cysteine mutated on the inactive mutant. Blue arrow-
heads indicate the C-terminal truncation mutants. The lysines that
can be conjugated to either SUMO (K99 and K141) or ubiquitin
(K99) are highlighted. The SUMO Interacting Motif (SIM), which
partially overlaps the first UIM is also indicated (from Meulmee-
ster et al., 2008).
Found at: doi:10.1371/journal.pone.0005571.s001 (6.61 MB TIF)
Figure S2 UBDs do not alter USP25m subcellular localization.
USP25m localization was monitored by immunohistochemistry
using a polyclonal antibody against USP25. Localization of full
length USP25m and deletion mutants is predominantly cytosolic,
with certain accumulation in the perinuclear region. Transfection
of full length USP25m, or the deletion mutants, does not affect
distribution of Ub, as assessed by immunodetection with an anti
Ub antibody.
Found at: doi:10.1371/journal.pone.0005571.s002 (2.19 MB
DOC)
Figure S3 USP25 is sumoylated, phosphorylated and acetylated.
A. USP25m is sumoylated. USP25m and all the UBD deletion
mutants display an extra higher molecular weight band (asterisk)
after in vitro sumoylation assays with SUMO-1 (middle lanes) and
SUMO-2 (right lanes). In the case of USP25m lacking both UBA
and UIM1, the band corresponding to SUMO-USP25m is weaker
(two asterisks). Note that the absence of all three UBDs rendered
similar levels of USP25m sumoylation to that of the full-length
protein. B. USP25m is phosphorylated. Myc-tagged USP25m and
USP25mC178S were immunoprecipitated with Myc antibodies
and detected in Western blots with pan-anti-Phospho-Ser and
pan-anti-phospho-Tyr. Bands appearing at the size corresponding
to USP25m indicate that USP25m is phosphorylated both in
serine(s) and threonine(s) (1st and 2nd panel, middle lane). This
band also appears when expressing USP25mC178S, indicating
that USP25m phosphorylation occurs irrespectively of its catalytic
activity (1st and 2nd panel, right lane). Membranes were stripped
and detected with a Myc antibody to confirm that the band
corresponded to USP25m (3rd panel). Immunoprecipitation
inputs were assessed with antibodies against phosphorylated
AKT and Myc as phosphorylation and transfection controls
respectively (4th and 5th panels). C. USP25m is acetylated. Myc-
tagged USP25m and USP25mC178S were immunoprecipitated
with Myc antibodies and detected in Western blots with pan-anti-
acetylated-Lys. Bands appearing at the USP25m size indicate it is
acetylated, both WT and C178S (upper panel). The same
membrane was stripped and detected with anti-Myc to confirm
the identity of the bands (2nd panel). Immunoprecipitation inputs
were assessed with antibodies against acetylated p53, Myc and a-
Tubulin as acetylation, transfection and loading controls, respec-
tively (3rd, 4th and 5th panels).
Found at: doi:10.1371/journal.pone.0005571.s003 (1.01 MB
DOC)
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